← Back to Patent Explorer
US4361580A Expired / Lapsed US ⏱️ 0.0 years remaining

Aluminum ibuprofen pharmaceutical suspensions

Assignee: Pharmacia and Upjohn Co
•
Filing: 1981-05-11
•
Granted: 1982-11-30
•
Expires: 2001-05-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Aluminum ibuprofen pharmaceutical liquid suspensions having improved resistance to dissolution rate reduction upon storage containing aluminum ibuprofen, a suspending agent have a particle size below 50 microns, a water-soluble surface active agent, water, and preferably also from 5 to 30 grams of sucrose per 100 ml of suspension are disclosed, or its sweetening equivalent of glucose, fructose, sodium saccharin sodium cyclamate, or mixtures thereof.

Inventors

  • 👤 Susanne M. Peck
  • 👤 Lois J. Larion
  • 👤 Englebert L. Rowe

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 18:30
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0087; A61K9/0095; A61K31/00; A61K31/185; A61K31/19; C; C07; C07C; C07C57/00; C07C57/30

Claims Analysis

Total Claims: 16
Claim 1
Independent Claim 86 words
A pharmaceutical liquid suspension composition consisting essentially of, for each 100 ml of suspension, (a) from about 4 to about 17 gms of an aluminum salt of ibuprofen, (b) from about 0.2 to about 1.1 gms of a pharmaceutically acceptable suspending agent having an average particle size below about 50 microns, (c) from about 0.3 to about 0.7 gms of a non-toxic pharmaceutically acceptable essentially water soluble surface active agent, and (d) sufficient water to bring the liquid volume to 100 ml of total liquid suspension.
Claim 2
Dependent Claim 86 words
A pharmaceutical liquid suspension composition consisting essentially of, for each 100 ml of suspension, (a) from about 4 to about 17 gms of an aluminum salt of ibuprofen, (b) from about 0.2 to about 1.1 gms of a pharmaceutically acceptable suspending agent having an average particle size below about 50 microns, (c) from about 0.3 to about 0.7 gms of a non-toxic pharmaceutically acceptable essentially water soluble surface active agent, and (d) sufficient water to bring the liquid volume to 100 ml of total liquid suspension.
Claim 3
Dependent Claim 40 words
A composition according to claim 1 which further includes (e) from 5 to about 30 gms of sucrose, or its sweetening equivalent of a compound selected from the group consisting of fructose, glucose, sodium saccharin, sodium cyclamate or mixtures thereof.
Claim 4
Dependent Claim 85 words
A composition according to claims 1 or 2 wherein the suspending agent is selected from a group consisting of (1) a mixture of about 0.18 to about 1.0 weight percent of microcrystalline cellulose and about 0.02 to about weight percent of sodium carboxymethylcellulose, (2) and about 0.12 to about 1.0 weight percent of magnesium aluminum silicate powder, and (3) mixtures of (1) and (2), so that the total weight of the suspending agent (1) and (2) to mixture is not more than about 1.1 percent.
Claim 5
Dependent Claim 34 words
A composition according to claims 1 or 2 which further includes up to about 10 ml of 95% ethanol for each 100 ml of suspension before the last of the q.s. water is added.
Claim 6
Dependent Claim 34 words
A composition according to claims 1 or 2 which further includes up to about 0.3 mg of sorbic acid for each 100 ml of suspension before the last of the q.s. water is added.
Claim 7
Dependent Claim 19 words
A composition according to claim 2 which includes as component (e) from 5 to about 30 grams of sucrose.
Claim 8
Dependent Claim 29 words
A composition according to claims 1 or 2 which further contains one or more flavoring and coloring agents as required, before the last of the q.s. water is added.
Claim 9
Dependent Claim 31 words
A composition according to claims 1 or 2 wherein the aluminum ibuprofen salt is one having an average ratio of between about 1 and 2 ibuprofen acid equivalents per aluminum atom.
Claim 10
Dependent Claim 30 words
A composition according to claims 1 or 2 wherein the aluminum ibuprofen salt is one having a ratio of about 2 ibuprofen equivalents per atom of aluminum in the salt.
Claim 11
Dependent Claim 177 words
A composition according to claim 2 which consists essentially of, for each 100 ml of suspension, (a) about 4.4 to about 14 gms of aluminum ibuprofen salt, which will provide about 4 to about 12 gms of ibuprofen equivalent in a suspension composition; (b) about 0.2 to about 1.1 gms of a suspending agent mixture consisting of about 0.18 to about 1.0 gm of microcrystalline cellulose and about 0.02 to about 0.12 gm of sodium carboxymethylcellulose; (c) about 0.3 to about 0.7 gm of a polyoxyethylenesorbitan monoC 16 to C 20 -alkanoic surfactant containing an average of about 18 to about 22 ethyleneoxy groups per surfactant molecule; (d) from about 10 to about 25 gms of granular U.S.P. sucrose; (e) from about 0.1 to about 0.3 gm of sorbic acid NF; (f) from about 0.032 to about 0.05 ml of artificial cherry-vanilla flavor, (g) 10% v/v hydrochloric acid aqueous solution, q.s. (for pH adjustment); (h) 10% w/v sodium hydroxide aqueous solution, q.s. (for pH adjustment); (i) purified water q.s. to make 100 ml of the liquid suspension.
Claim 12
Dependent Claim 27 words
A composition according to claims 1 or 2 wherein the aluminum ibuprofen salt is one having a surface area of at least 7.0 square meters per gram.
Claim 13
Dependent Claim 21 words
A composition according to claim 2 which includes as component (e) from about 6.25 grams to about 37.5 grams of glucose.
Claim 14
Dependent Claim 21 words
A composition according to claim 2 which includes as component (e) from about 2.94 grams to about 17.65 grams of fructose.
Claim 15
Dependent Claim 22 words
A composition according to claim 2 which includes as component (e) from about 5 milligrams to about 60 milligrams of sodium saccharin.
Claim 16
Dependent Claim 23 words
A composition according to claim 2 which further includes as component (e) from about 166 milligrams to about 1 gram of sodium cyclamate.

References Cited (Backward Citations)

US3228831A Cited
US3385886A Cited
US3600437A Cited
US3636200A Cited
US3865857A Cited
US3976674A Cited
US3985779A Cited
BE811810A Cited
US4031243A Cited
US4145440A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-11-29 1986-05-31 1986-11-30 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-11-29 1990-05-31 1990-11-30 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-11-29 1994-05-31 1994-11-30 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag